216 related articles for article (PubMed ID: 2961356)
1. Dichloromethylene diphosphonate action in hematologic and other malignancies.
Canfield RE; Siris ES; Jacobs TP
Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
[TBL] [Abstract][Full Text] [Related]
2. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma.
Siris ES; Sherman WH; Baquiran DC; Schlatterer JP; Osserman EF; Canfield RE
N Engl J Med; 1980 Feb; 302(6):310-5. PubMed ID: 6444241
[TBL] [Abstract][Full Text] [Related]
3. [Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author's transl)].
Delmas P; Chapuy MC; Vignon E; Briançon D; Charhon S; Meunier PJ
Nouv Presse Med; 1982 Apr; 11(19):1471-4. PubMed ID: 6210878
[TBL] [Abstract][Full Text] [Related]
4. Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.
Chapuy MC; Meunier PJ; Alexandre CM; Vignon EP
J Clin Invest; 1980 May; 65(5):1243-7. PubMed ID: 6444955
[TBL] [Abstract][Full Text] [Related]
5. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
Siris ES; Hyman GA; Canfield RE
Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577
[TBL] [Abstract][Full Text] [Related]
6. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.
Attardo-Parrinello G; Merlini G; Pavesi F; Crema F; Fiorentini ML; Ascari E
Arch Intern Med; 1987 Sep; 147(9):1629-33. PubMed ID: 2957971
[TBL] [Abstract][Full Text] [Related]
7. Use of dichloromethylene diphosphonate in metastatic bone disease.
Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
10. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
[TBL] [Abstract][Full Text] [Related]
11. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
[TBL] [Abstract][Full Text] [Related]
12. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma.
Paterson AD; Kanis JA; Cameron EC; Douglas DL; Beard DJ; Preston FE; Russell RG
Br J Haematol; 1983 May; 54(1):121-32. PubMed ID: 6221750
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Laine H
Cancer Treat Rep; 1984 Apr; 68(4):655-7. PubMed ID: 6231989
[TBL] [Abstract][Full Text] [Related]
14. Clodronate in the medical management of hyperparathyroidism.
Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP).
Conte N; Di Virgilio R; Roiter I; Caberlotto L
Tumori; 1985 Feb; 71(1):51-4. PubMed ID: 3157251
[TBL] [Abstract][Full Text] [Related]
16. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
17. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
18. Treatment of skeletal disease in breast cancer: a controlled clodronate trial.
Elomaa I; Blomqvist C; Porkka L; Lamberg-Allardt C; Borgström GH
Bone; 1987; 8 Suppl 1():S53-6. PubMed ID: 2961355
[TBL] [Abstract][Full Text] [Related]
19. Clodronate for osteolytic metastases due to breast cancer.
Elomaa I; Blomqvist C; Porkka L; Holmström T; Taube T; Lamberg-Allardt C; Borgström GH
Biomed Pharmacother; 1988; 42(2):111-6. PubMed ID: 2971403
[TBL] [Abstract][Full Text] [Related]
20. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]